From: Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States
 | Cemiplimab | Nivolumab | Pembrolizumab | Atezolizumab | Avelumab | Durvalumab | Ipilimumab |
---|---|---|---|---|---|---|---|
Number/ratio | Number/ ratio | Number/ ratio | Number/ ratio | Number/ratio | Number/ ratio | Number/ratio | |
BL | 49/0.078 | 4,336/0.051 | 2,975/0.057 | 2,070/0.097 | 163/0.064 | 604/0.075 | 438/0.054 |
CD | 35/0.056 | 3,947/0.046 | 2,117/0.040 | 1,074/0.050 | 151/0.060 | 435/0.054 | 561/0.069 |
ELD | 1/0.002 | 382/0.004 | 177/0.003 | 93/0.004 | 7/0.003 | 29/0.004 | 18/0.002 |
EnD | 25/0.040 | 4,346/0.051 | 2,234/0.043 | 848/0.040 | 124/0.049 | 289/0.036 | 289/0.036 |
ED | 8/0.013 | 1,664/0.019 | 919/0.018 | 269/0.013 | 27/0.011 | 108/0.013 | 78/0.010 |
GD | 62/0.099 | 11,231/0.131 | 6,505/0.124 | 3,093/0.145 | 357/0.141 | 939/0.117 | 1,233/0.152 |
HD | 50/0.080 | 4,666/0.055 | 3,009/0.057 | 1,405/0.066 | 133/0.053 | 463/0.058 | 553/0.068 |
ID | 33/0.053 | 1,539/0.018 | 1,151/0.022 | 366/0.017 | 60/0.024 | 84/0.010 | 98/0.012 |
MnD | 39/0.062 | 6,095/0.071 | 3,012/0.058 | 1,494/0.070 | 173/0.068 | 342/0.043 | 490/0.060 |
McD | 30/0.048 | 5,544/0.065 | 3,280/0.063 | 1,029/0.048 | 145/0.057 | 418/0.052 | 335/0.041 |
NMU | 36/0.057 | 10,113/0.118 | 6,764/0.129 | 1,121/0.053 | 153/0.060 | 1,008/0.126 | 1,781/0.220 |
NsD | 69/0.110 | 7,168/0.084 | 4,278/0.082 | 1,990/0.093 | 243/0.096 | 627/0.078 | 559/0.069 |
PD | 16/0.025 | 1,836/0.021 | 1,136/0.022 | 381/0.018 | 45/0.018 | 148/0.018 | 159/0.020 |
RuD | 31/0.49 | 3,827/0.045 | 2,661/0.051 | 1,261/0.059 | 162/0.064 | 259/0.032 | 382/0.047 |
RB | 3/0.005 | 259/0.003 | 205/0.004 | 95/0.004 | 6/0.002 | 20/0.002 | 14/0.002 |
RTM | 73/0.116 | 9,317/0.109 | 5,755/0.110 | 2,429/0.114 | 277/0.110 | 1,526/0.190 | 849/0.105 |
SSD | 40/0.064 | 6,631/0.078 | 4,414/0.084 | 1,362/0.064 | 168/0.066 | 439/0.055 | 1/0.000 |
VD | 28/0.045 | 2,550/0.030 | 1,743/0.033 | 918/0.043 | 135/0.053 | 283/0.035 | 271/0.033 |
Total number cases | 628 | 85,451 | 52,335 | 21,298 | 2,529 | 8,021 | 8,109 |